AMPK agonism optimizes the in vivo persistence and anti-leukemia efficacy of chimeric antigen receptor T cells
Erica Lynne Braverman, Mengtao Qin, Elisabet Ampudia-Mesias, Herbert Tres Schuler, Harrison Brown, Lukas Murdych, Ann Titus, Allison MacLean, Bhavya Kanagala, Christopher Wittmann, Archana Ramgopal, Felicia Kemp, Steven J Mullet, Aaron Yang, Amanda C. Poholek, , Craig Byersdorfer
This study shows that activating AMPK during CAR T cell expansion improves their in vivo persistence and anti-leukemia efficacy without altering expansion protocols or genetic constructs.
Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology